Thrivent Financial for Lutherans Has $10.35 Million Stake in Enovis Co. (NYSE:ENOV)

Thrivent Financial for Lutherans reduced its stake in shares of Enovis Co. (NYSE:ENOV) by 86.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 240,435 shares of the company’s stock after selling 1,579,438 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Enovis were worth $10,351,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Ridgewood Investments LLC purchased a new position in Enovis in the second quarter valued at about $44,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Enovis in the 3rd quarter valued at approximately $55,000. Innealta Capital LLC acquired a new position in Enovis in the second quarter worth approximately $65,000. Benjamin F. Edwards & Company Inc. raised its position in Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after acquiring an additional 371 shares in the last quarter. Finally, Cetera Advisors LLC acquired a new stake in Enovis in the first quarter valued at approximately $239,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Stock Up 3.3 %

ENOV stock opened at $46.27 on Friday. Enovis Co. has a twelve month low of $38.27 and a twelve month high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.59 billion, a PE ratio of -20.90 and a beta of 1.91. The business’s 50-day simple moving average is $42.57 and its 200 day simple moving average is $45.03.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to analysts’ expectations of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 earnings per share. On average, research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Evercore ISI reduced their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities assumed coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. cut their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.